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Introduction
Helicobacter pylori infection is closely related to gastric atro-
phy, intestinal metaplasia (IM), and progression to dysplasia or 
cancer.1 However, the incidence of gastric cancer did not differ 
between Chinese patients receiving H. pylori eradication treat-
ment and those receiving placebo during 7.5 years of follow-up.2 
Several reports exist on the effect of H. pylori eradication in pa-
tients at a high risk for gastric cancer. Previous studies illustrated 
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Purpose: The importance of Helicobacter pylori eradication after endoscopic resection (ER) of gastric neoplasms remains controversial. 
In this study, we clarified the importance of H. pylori eradication for metachronous lesions after ER. 
Materials and Methods: This study included 3,882 patients with gastric neoplasms who underwent ER. We included patients infected 
with H. pylori who received eradication therapy. Among them, 34 patients with metachronous lesions after ER and 102 age- and sex-
matched patients (nonmetachronous group) were enrolled. Background mucosal pathologies such as atrophy and intestinal metaplasia 
(IM) were evaluated endoscopically. The expression levels of CDX1, CDX2, Sonic hedgehog (SHH), and SOX2 were evaluated based on H. 
pylori eradication and the development of metachronous lesions.
Results: The eradication failure rate was higher in the metachronous group than in the nonmetachronous group (P=0.036). Open-
type atrophy (P=0.003) and moderate-to-severe IM (P=0.001) occurred more frequently in the metachronous group. In patients with 
an initial diagnosis of dysplasia, the eradication failure rate was higher in the metachronous group than in the nonmetachronous group 
(P=0.002). In addition, open-type atrophy was more frequent in the metachronous group (P=0.047). In patients with an initial diag-
nosis of carcinoma, moderate-to-severe IM occurred more frequently in the metachronous group (P=0.003); however, the eradication 
failure rate was not significantly different between the two groups. SHH and SOX2 expression was increased, and CDX2 expression was 
decreased in the nonmetachronous group after eradication (P<0.05).
Conclusions: Open-type atrophy, moderate-to-severe IM, and H. pylori eradication failure were significantly associated with metachro-
nous lesions. However, eradication failure was significantly associated with dysplasia, but not carcinoma, in the metachronous group. 
Thus, H. pylori eradication may play an important role in preventing metachronous lesions after ER for precancerous lesions before car-
cinomatous transformation.
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that eradication of H. pylori after endoscopic resection (ER) of 
early gastric cancer (EGC) helped prevent the development of 
metachronous gastric cancer.3,4 However, Choi et al.5 revealed 
that H. pylori eradication after ER of EGC did not reduce the 
incidence of metachronous gastric cancer. Therefore, the impor-
tance of H. pylori eradication after ER for gastric neoplasms re-
mains controversial. Defining the subgroup of patients for whom 
H. pylori eradication after ER for gastric neoplasms is beneficial 
is important because patients who undergo ER is increasing and 
the incidence of metachronous lesions is also consequently in-
creasing. 
Several gastric and intestinal epithelial markers are associ-
ated with the progression of IM, a precancerous lesion.6,7 Sonic 
hedgehog (SHH) is an essential regulator of developmental and 
physiological processes.8-10 In humans, Shh mRNA and SHH 
protein are expressed in the normal gastric fundus but not in the 
esophagus and intestine.11,12 Loss of SHH is an early change as-
sociated with the presence of IM.11,13 CDX proteins (intestine-
specific caudal-related homeobox transcription factor) are 
intestine-specific transcription factors encoded by human CDX1 
and CDX2 genes. Moreover, Mizoshita et al.14 reported that the 
expression of CDX1 and CDX2 was found in IM of the human 
stomach. Shiotani et al.7 demonstrated the reexpression of SHH 
and reduction of CDX2 levels after H. pylori eradication. Sox2, 
a gastric transcription factor, is expressed in the human stom-
ach, and its expression gradually decreases as IM progresses.15 
That is, Sox2 expression decreases and Cdx expression increases 
gradually during the progression of IM. Therefore, these mark-
ers might help identify patients for whom H. pylori eradication 
is advantageous. In this study, we evaluated the clinicopatho-
logical factors and gastric and intestinal markers according to 
the development of metachronous gastric neoplasms after ER, 
clarified the role of H. pylori eradication in the development of 
metachronous lesions, and investigated the patient subgroup for 
whom H. pylori eradication was beneficial, especially after ER.
Materials and Methods 
1. Patients
Between June 2006 and June 2012, gastric neoplasms were 
diagnosed in 3,882 patients and treated with ER. Among the 
patients, we identified those who were infected with H. pylori 
and received H. pylori eradication treatment; that is, all patients 
included in this study received H. pylori eradication treat-
ment. After the H. pylori eradication treatment, 34 patients with 
metachronous gastric neoplasms after ER for gastric neoplasms 
(metachronous group) and 102 age- and sex-matched patients 
(nonmetachronous) who underwent ER for gastric neoplasms 
and who did not develop metachronous gastric neoplasms were 
enrolled on the basis of propensity score matching at a ratio 
of 1:3. The metachronous and nonmetachronous groups were 
matched according to age and sex by using propensity score 
matching. We defined metachronous lesions as those that devel-
oped at another site (not a previous ER site) at 6 months or later 
after the previous ER. The period between the development of 
metachronous gastric neoplasms and H. pylori eradication was 
at least 6 months, to accurately evaluate the effect of H. pylori 
eradication on the incidence of metachronous lesions after ER.4 
In addition, there was a median interval of 3 months (range, 
0~32 months) between ER and H. pylori eradication. To deter-
mine the H. pylori infection status, rapid urease and urea breath 
tests and histological assessment were done. Patients who had a 
positive result for at least one of these tests were defined as the 
group with a positive H. pylori infection. In contrast, those who 
showed negative results for all three examinations were defined 
as the group with negative H. pylori infection. The first eradica-
tion regimen was conventional triple therapy consisting of stan-
dard doses of a proton pump inhibitor (PPI) twice daily, 1,000 
mg amoxicillin twice daily, and 500 mg clarithromycin twice 
daily for 7 to 14 days. In addition, in cases of eradication failure 
with the initial conventional triple therapy, quadruple therapy 
including two standard doses of a PPI, 500 mg metronidazole 
thrice daily, 120 mg bismuth four times daily, and 500 mg tetra-
cycline four times daily for 7 to 14 days was used. The patients 
were evaluated in terms of their clinicopathological characteris-
tics, such as age, sex, tumor location, gross appearance of the tu-
mor, tumor histological type, tumor size, tumor invasion depth, 
tumor multiplicity, the presence of ulcers, background mucosa, 
and H. pylori eradication failure rate. Atrophy and IM were 
evaluated endoscopically at the time of ER. In particular, atro-
phic gastric mucosa was categorized by using the Kimura clas-
sification.16,17 The severity of atrophy was categorized as open or 
closed, and that of IM was classified as none, mild, moderate, or 
severe. Mild grade was characterized as metaplastic mucosa with 
fine or granular plaques. Moderate grade was defined as coarse 
plaques or patches. Severe grade was characterized as mucosa 
with coarser and larger plaques or patches.17 H. pylori infection 
was evaluated via histopathological examinations of the resected 
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specimen, the urea breath test, or the rapid urease test. The 
clinicopathological characteristics were analyzed retrospectively 
and compared between the metachronous and nonmetachronous 
groups. The median period between the initial resection and the 
subsequent identification of metachronous neoplasm was 30.1 
months (range, 9.5~74.1 months), and that between the initial 
resection and the determination of no neoplasm (nonmetachro-
nous group) was 49.1 months (range, 16.7~92.7 months). We 
excluded metachronous recurrence occurring within 6 months 
because the lesions detected during this time were most likely 
lesions that were missed before and that should be categorized as 
synchronous cancers or neoplasms. 
The Institutional Review Board of Severance and Gangnam 
Severance Hospital approved this study (3-2014-0117).
2. Immunohistochemistry
Immunohistochemical staining was performed for SHH, 
CDX1, CDX2, and SOX2. Twenty patients were selected for im-
munohistochemistry on the basis of the development of meta-
chronous neoplasms before and after H. pylori eradication, with 
10 specimens obtained from each group both before and after 
H. pylori eradication. Immunohistochemical staining was per-
formed after H. pylori eradication at the time of the subsequent 
identification of metachronous neoplasm (metachronous group, 
median 30.1 months) and the determination of no neoplasm 
(nonmetachronous group, median 49.1 months). Biopsy speci-
mens were obtained from the antrum and corpus for evaluating 
the background mucosa by using immunohistochemical staining. 
We used paraffin-embedded tissue specimens and rabbit poly-
clonal anti-SHH (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), goat polyclonal anti-SOX2 (Santa Cruz Biotechnology), 
mouse monoclonal anti-CDX1 (Santa Cruz Biotechnology), 
and rabbit polyclonal anti-CDX2 (Santa Cruz Biotechnology) 
antibodies. The expression levels were determined by scoring 
both the positivity rate and intensity of SHH, CDX1, CDX2, 
and SOX2 staining. The positive expression rate was determined 
by counting the number of immunopositive cells in three areas 
randomly chosen in the tissue for a total of 300 cells and scored 
(0=0%, 1=1%~25%, 2=26%~35%, 3=36%~45%, 4=46%~65%, 
5=66%~100%). The staining intensity was scored as follows: 0, 
no detectable cytoplasmic staining; 1, mild cytoplasmic stain-
ing; 2, moderate cytoplasmic staining; and 3, severe cytoplasmic 
staining. The two scores were then summed to obtain a final 
score between 0 and 8.
3. Statistical analysis
The chi-square test and Fisher exact test were used to com-
pare the clinicopathological factors between the groups accord-
ing to the development of metachronous gastric neoplasms. The 
t-test was used for noncategorical variables in the intergroup 
comparisons of clinicopathological characteristics. The Wilcoxon 
signed-rank test and Mann-Whitney U-test were used for 
evaluating immunohistochemical expression levels. The meta-
Table 1. Comparisons of the clinicopathologic findings between the 
metachronous and control groups
Variable Metachronous group (n=34)
Control group 
(n=102) P-value
Age (yr) 62.1±7.0 63.1±7.5 0.495
Sex (male) 26 (76.5) 78 (76.5) 1.000
Tumor size (mm) 11.0±9.3 11.7±7.5 0.659
Multiplicity 4 (11.8) 13 (12.7) 1.000
Location 0.351
   Upper 3 (8.8) 7 (6.9)
   Middle 13 (38.2) 27 (26.5)
   Lower 18 (52.9) 68 (66.7)
Macroscopic type 0.247
   Elevated 21 (61.8) 76 (74.5)
   Flat 11 (32.4) 19 (18.6)
   Depressed 2 (5.9) 7 (6.9)
Ulcer 18 (52.9) 52 (51.0) 1.000
Atrophy* 0.003
   Open 23 (67.6) 36 (35.3)
   Close 8 (23.5) 39 (38.2)
   No 3 (8.8) 27 (26.5)
Intestinal metaplasia* 0.001
   No 1 (2.9) 20 (19.6)
   Mild 25 (73.5) 75 (73.5)
   Moderate 4 (11.8) 7 (6.9)
   Severe 4 (11.8) 0 (0.0)
Histopathology 0.912
   Low-grade dysplasia 10 (29.4) 29 (28.4)
   High-grade dysplasia 4 (11.8) 15 (14.7)
   Carcinoma 20 (58.8) 58 (56.9)
Helicobacter pylori eradication 0.036
   Success 26 (76.5) 93 (91.2)
   Failure 8 (23.5) 9 (8.8)
Values are presented as mean±standard deviation or number (%). 
*Background mucosal pathologies, such as atrophy and intestinal 
metaplasia, were evaluated endoscopically.
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chronous and nonmetachronous groups were matched according 
to age and sex by using propensity score matching at a ratio of 1:3. 
Statistical significance was set at P＜0.05. All statistical analyses 
were performed by using SPSS ver. 12.0 for Windows (SPSS 
Inc., Chicago, IL, USA).
Results
1. Clinicopathological characteristics of the 
metachronous and nonmetachronous groups
The clinicopathological features of 34 patients with meta-
chronous gastric neoplasms and 102 nonmetachronous patients 
are shown in Table 1. No differences were found in tumor size, 
multiplicity, location, macroscopic type, ulcer, and histology be-
tween the metachronous and nonmetachronous groups. Open-
type atrophy (P=0.003), moderate and severe IM (P=0.001), and 
failure of H. pylori eradication (P=0.036) occurred more fre-
quently in the metachronous group (Table 1). 
2. Demographic and clinicopathological characteristics 
of the metachronous and nonmetachronous 
groups according to histopathology 
Of the 136 patients who underwent ER for gastric neo-
plasms, 58 (42.6%) underwent ER for dysplasia and 78 (57.4%) 
Table 2. Comparisons of the clinicopathologic findings between the 
metachronous and control groups in patients with dysplasia
Variable Metachronous group (n=14)
Control  
group (n=44) P-value
Age (yr) 63.6±7.0 62.4±7.3 0.579
Sex (male) 12 (85.7) 31 (70.5) 0.317
Tumor size (mm) 11.6±10.4 11.1±7.3 0.841
Multiplicity 2 (14.3) 5 (11.4) 1.000
Location 0.326
   Upper 1 (7.1) 3 (6.8)
   Middle 6 (42.9) 10 (22.7)
   Lower 7 (50.0) 31 (70.5)
Macroscopic type 0.030
   Elevated 7 (50.0) 36 (81.8)
   Flat 6 (42.9) 5 (11.4)
   Depressed 1 (7.1) 3 (6.8)
Ulcer 7 (50.0) 9 (20.5) 0.043
Atrophy* 0.047
   Open 10 (71.4) 15 (34.1)
   Close 3 (21.4) 19 (43.2)
   No 1 (7.1) 10 (22.7)
Intestinal metaplasia* 0.194
   No 1 (7.1) 10 (22.7)
   Mild 11 (78.6) 30 (68.2)
   Moderate 1 (7.1) 4 (9.1)
   Severe 1 (7.1) 0 (0.0)
Helicobacter pylori eradication 0.002
   Success 10 (71.4) 44 (100.0)
   Failure  4 (28.6) 0 (0.0)
Values are presented as mean±standard deviation or number (%). 
*Background mucosal pathologies, such as atrophy and intestinal 
metaplasia, were evaluated endoscopically.
Table 3. Comparisons of the clinicopathologic findings between the 
metachronous and control groups in patients with carcinoma
Variable Metachronous group (n=20)
Control  
group (n=58) P-value
Age (yr) 61.0±7.0 63.6±7.7 0.184
Sex (male) 14 (70.0) 47 (81.0) 0.351
Tumor size (mm) 11.9±10.3 12.1±7.7 0.954
Multiplicity 2 (10.0) 8 (13.8) 1.000
Location 0.767
   Upper 2 (10.0) 4 (6.9)
   Middle 7 (35.0) 17 (29.3)
   Lower 11 (55.0) 37 (63.8)
Macroscopic type 0.956
   Elevated 14 (70.0) 40 (69.0)
   Flat 5 (25.0) 14 (24.1)
   Depressed 1 (5.0) 4 (6.9)
Ulcer 11 (55.0) 43 (74.1) 0.159
Atrophy* 0.063
   Open 13 (65.0) 21 (36.2)
   Close 5 (25.0) 20 (34.5)
   No 2 (10.0) 17 (29.3)
Intestinal metaplasia* 0.003
   No  0 (0.0) 10 (17.2)
   Mild 14 (70.0) 45 (77.6)
   Moderate 3 (15.0) 3 (5.2)
   Severe 3 (15.0) 0 (0.0)
Helicobacter pylori eradication 0.730
   Success 16 (80.0) 49 (84.5)
   Failure 4 (20.0) 9 (15.5)
Values are presented as mean±standard deviation or number (%). 
*Background mucosal pathologies, such as atrophy and intestinal 
metaplasia, were evaluated endoscopically.
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underwent ER for carcinoma. In patients with dysplasia, en-
doscopically flat-type lesions (P=0.030), ulcers (P=0.043), and 
open-type atrophy (P=0.047) were found predominantly in the 
metachronous group. The failure rate of H. pylori eradication 
was significantly higher in the metachronous group than in the 
nonmetachronous group (P=0.002) (Table 2). In patients with 
carcinoma, moderate-to-severe IM was observed more fre-
quently in the metachronous group (P=0.003). The failure rate of 
H. pylori eradication was not different between the metachro-
nous and nonmetachronous groups (P=0.730) (Table 3).
3. Immunohistochemistry
To investigate gastric and intestinal markers according to the 
development of metachronous gastric neoplasms after ER, im-
munohistochemical staining was performed for 10 metachronous 
and 10 nonmetachronous patients before and after H. pylori 
eradication (Fig. 1). The intensities of SOX2 staining in the an-
trum and SHH staining in the antrum and corpus were increased 
in the nonmetachronous group after H. pylori eradication (P＜ 
0.05). In addition, the intensity of CDX2 staining in the antrum 
and corpus was decreased in the nonmetachronous group after H. 
pylori eradication (P＜0.05). However, such changes in the in-
A B
C D
Fig. 1. Protein expression of SOX2, sonic hedgehog (SHH), CDX2, and CDX1 in the background gastric mucosa (×400). (A, B) Immunohisto-
chemical staining for SOX2. Nuclear SOX2 expression increases after Helicobacter pylori eradication in the nonmetachronous group (A) in which 
metachronous gastric neoplasms do not arise (B). (C, D) Immunohistochemical staining for CDX2. The nuclear expression of CDX2 decreases after 
H. pylori eradication in the nonmetachronous group (D) in which metachronous gastric neoplasms do not arise (C). (E, F) Immunohistochemical 
staining for SHH. Cytoplasmic SHH expression increases after H. pylori eradication in the nonmetachronous group (E) in which metachronous gastric 
neoplasms do not arise (F). (G, H) Immunohistochemical staining for CDX1. The nuclear expression of CDX1 is not significantly different after H. py-
lori eradication between the nonmetachronous and metachronous groups. (G) Positive CDX1 expression; (H) negative CDX1 expression.
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tensity of SOX2, SHH, and CDX2 staining were not observed in 
the metachronous group. The intensity of SOX2 and SHH stain-
ing in the antrum after H. pylori eradication was significantly 
lower in the metachronous group than in the nonmetachronous 
group (P＜0.05). Moreover, the intensity of CDX2 staining in the 
antrum before H. pylori eradication was significantly higher in the 
metachronous group than in the nonmetachronous group (P＜0.05) 
(Table 4).
Discussion
The 5-year survival rate of EGC was favorable (＞95%).18 ER 
is currently accepted as a local treatment for EGC, and the long-
term outcome of ER for EGC in Korea is favorable.19,20 ER has 
the advantages of preserving the entire stomach and increasing 
the postoperative quality of life of patients; however, the risk 
of synchronous or metachronous gastric cancer may be higher 
in the remnant stomach compared with that after gastrectomy. 
Metachronous gastric cancer developed in 2.7% to 14.0% of pa-
tients after ER within 3 to 5 years.21,22 Multiple gastric lesions are 
more frequent in EGC than in advanced gastric cancer. There-
fore, the detection of metachronous lesions after ER is important 
during follow-up after ER. In addition, identifying patients at a 
high risk of developing metachronous lesions and investigating 
the clinicopathological factors associated with metachronous le-
sions are clinically important.
Chronic H. pylori infection is associated with gastric cancer; 
however, the effect of H. pylori eradication on the prevention of 
metachronous gastric cancers remains controversial. Choi et al.5 
reported that H. pylori eradication after ER of gastric tumor did 
E F
G H
Fig. 1. Continued.
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not reduce the incidence of metachronous gastric carcinoma. In 
this study, persistent H. pylori infection was found in 80 of 439 
patients who underwent H. pylori eradication therapy. More-
over, metachronous gastric cancer developed in 10 patients in 
whom H. pylori had been eradicated (10 of 439, 2.3%). Accord-
ing to histology, metachronous gastric cancer developed in three 
patients with dysplasia (3 of 226, 1.3%) and seven patients with 
carcinoma (7 of 213, 3.3%) after H. pylori eradication. Kwon et 
al. reported that persistent H. pylori infection was significantly 
associated with metachronous gastric cancer. The incidence of 
metachronous gastric lesions was significantly higher in patients 
with persistent H. pylori infection than in those in whom the 
bacterium was eradicated (18.8% vs. 8.4%, P=0.016).23
In the present study, all patients were infected with H. py-
lori and received H. pylori eradication treatment. We selected 
such a subgroup because we wanted to identify the patients for 
whom H. pylori eradication treatment would be helpful. Previ-
ous studies3,5 reported controversial results about the effects of H. 
pylori eradication treatment on metachronous gastric neoplasms. 
Therefore, we selected patients who received H. pylori eradica-
tion treatment, and then investigated the clinicopathological fac-
tors that affected the development of metachronous neoplasms. 
In this study, the number of patients with metachronous gastric 
neoplasms after ER was 34 (14 with dysplasia, 20 with carci-
noma). However, the number of patients with metachronous 
gastric neoplasms was not small. Similar to previous studies, 
metachronous recurrence was observed in 33 patients during 3 
years of follow-up3 and in 27 patients during 3 years of follow-
up.5 Although the 3,882 patients were found to have gastric neo-
plasms and were scheduled for ER, the final group for the study 
consisted of 136 patients because we focused on those patients 
who received H. pylori eradication treatment. In addition, we 
investigated the role of H. pylori infection on the development 
of metachronous lesions by comparing the failure rate of H. 
pylori eradication; that is, we assessed the effect of persistent H. 
pylori infection on metachronous lesions after ER. Open-type 
atrophy, severe IM, and failure of H. pylori eradication were 
significantly associated with metachronous gastric neoplasms. 
Notably, failure of H. pylori eradication was significantly more 
frequent in metachronous patients with gastric dysplasia but not 
Table 4. Expression of SOX2, SHH, CDX2, and CDX1 proteins in background gastric mucosa 
Variable
Control group (n=10) Metachronous group (n=10)
Antrum Corpus Antrum Corpus
SOX2†
   Before eradication 3.0 (2.0~3.0)† 3.0 (2.0~4.5) 3.5 (2.0~4.3) 3.0 (2.0~3.3)
   After eradication 3.0 (2.0~5.3)*,† 2.5 (2.0~5.3) 2.0 (2.0~2.0)* 2.0 (2.0~2.3)
SHH‡
   Before eradication 3.0 (2.8~5.3)‡ 5.0 (3.8~5.5)‡ 5.0 (4.0~5.3) 4.5 (3.0~6.0)
   After eradication 4.5 (3.8~6.0)*,‡ 7.0 (4.0~7.0)*,‡ 3.0 (2.8~4.0)* 4.0 (2.0~6.0)*
CDX2§
   Before eradication 4.0 (1.5~7.0)*,§ 6.0 (3.8~8.0)§ 7.5 (4.8~8.0)* 5.0 (2.0~8.0)
   After eradication 3.5 (0.0~6.3)§ 3.0 (1.5~7.3)§ 7.5 (4.5~8.0) 6.5 (5.8~8.0)
CDX1
   Before eradication 2.0 (2.0~4.5) 2.5 (2.0~5.3) 3.0 (2.0~3.3) 3.0 (2.0~5.3)
   After eradication 2.5 (2.0~3.5) 2.0 (2.0~2.3) 2.0 (2.0~2.8) 2.0 (2.0~3.0)
Values are presented as median (interquartile range). The Wilcoxon signed-rank test and Mann-Whitney U-test were used for evaluating the 
immunohistochemical expression levels. *P<0.05, compared between the control and metachronous groups. The expression levels were determined 
by scoring both the positive rate and the intensity of Sonic hedgehog (SHH), CDX1, CDX2, and SOX2 staining. The positive expression rate 
was determined by counting the number of immunopositive cells in three areas randomly chosen in the tissue in a total of 300 cells and given 
scores (0=0%, 1=1%~25%, 2=26%~35%, 3=36%~45%, 4=46%~65%, 5=66%~100%). The staining intensity was scored as follows: 0, no detectable 
cytoplasmic staining; 1, mild cytoplasmic staining; 2, moderate cytoplasmic staining; and 3, severe cytoplasmic staining. Two scores were then 
summed to obtain a final score of 0 and 8. †The expression of SOX2 staining in the antrum increases in the control group after Helicobacter pylori 
eradication. ‡The expression of SHH staining in the antrum and corpus increases in the control group after H. pylori eradication. §The expression 
of CDX2 staining in the antrum and corpus decreases in the control group after H. pylori eradication.
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those with carcinoma. 
McDonald et al. reported that genetic/epigenetic changes in 
IM would lead to dysplasia by identifying identical genetic al-
terations in dysplastic lesions and the surrounding IM; indeed, 
gastric cancer can arise from dysplastic lesions through further 
genetic alterations, referred to as ‘cancer in adenoma’.24,25 The 
causes of genetic and epigenetic changes in IM or dysplasia are 
diverse, and several genetic and epigenetic changes were re-
versed by H. pylori eradication. In this study, persistent H. pylori 
infection was significantly more frequent in patients with gastric 
dysplasia but not in those with carcinoma, in the metachronous 
group than in the nonmetachronous group. Therefore, H. pylori 
infection may affect the development of metachronous gastric 
neoplasms in patients with dysplasia or precancerous lesions 
before carcinomatous transformation. Only moderate-to-severe 
IM was significantly associated with carcinoma in the meta-
chronous group. The reason might be the ‘point of no return’ 
the point at which H. pylori eradication could no longer prevent 
metachronous lesions. Accurately defining the point of no return 
is difficult because the molecular process cannot be measured 
precisely. However, our data suggest that H. pylori eradication 
may be more effective before the status of the background mu-
cosa progresses to severe IM. 
Currently, H. pylori eradication for preventing metachronous 
gastric carcinoma after ER is permitted but is not covered by the 
Korean National Health Insurance. Meanwhile, H. pylori eradi-
cation is not covered for precancerous lesions such as atrophy, 
IM, or dysplasia because of the lack of sufficient data. However, 
in this study, the role of H. pylori eradication in the prevention 
of metachronous lesions was more important in dysplasia than 
in carcinoma. Therefore, H. pylori eradication would be more 
helpful in patients with dysplasia than in those with carcinoma 
after ER. Previous reports about the association between H. py-
lori eradication and metachronous lesions have focused on EGC. 
However, on the basis of our results, H. pylori eradication after 
ER should be performed in patients with dysplasia for the pre-
vention of metachronous lesions. 
Our study has some limitations. This study was retrospective, 
and H. pylori eradication treatment could not be randomized. 
In addition, the period between ER and H. pylori eradication 
varied. The background mucosa such as atrophy and IM were 
evaluated endoscopically, not histologically.
Bornschein et al.26 reported that the expression levels of 
CDX1, CDX2, and SOX2 were similar in gastric cancer and in 
the surrounding nontumorous mucosa. They compared the gene 
expression between the tumor and the tumor-distant mucosa. In 
addition, upregulation of CDX1 and CDX2 and downregulation 
of SOX2 in the nonneoplastic gastric mucosa of patients with 
gastric cancer were confirmed. Moreover, H. pylori infection 
had no significant effect on the regulation of CDX1, CDX2, and 
SOX2 at the gastric cancer stage. In this study, the expression 
of CDX2 decreased and that of SOX2 increased after H. pylori 
eradication in the nonmetachronous group in which metachro-
nous gastric neoplasm did not arise. The transgenic expression of 
cdx2 in the murine stomach can induce IM, which progresses to 
invasive gastric cancer.27 Furthermore, SOX2 is downregulated 
in gastric carcinoma.15,28 Therefore, the negative correlation of 
CDX2 and inverse relation with SOX2 expression in this study 
might be associated with the effects of H. pylori eradication on 
premalignant lesions before carcinoma. SHH expression also 
increased after H. pylori eradication in the nonmetachronous 
group. Shiotani et al.7 reported that H. pylori eradication was 
associated with an increase in SHH expression in the corpus, es-
pecially in the absence of incomplete IM. Incomplete IM at the 
corpus is more common in patients with gastric cancer,13 which 
is in agreement with our finding of a positive correlation with 
SHH expression in the nonmetachronous group after H. pylori 
eradication. In summary, the expression of SHH and SOX2 in-
creased and that of CDX2 decreased after H. pylori eradication 
in the nonmetachronous group in this study. Although the re-
sults were derived from a small sample size, these markers could 
be used to define the subgroup in which H. pylori eradication 
would be beneficial after ER.
In conclusion, H. pylori eradication can play an important 
role in the prevention of metachronous lesions after ER in 
patients with precancerous lesions before carcinomatous trans-
formation. In addition, the changes in SHH, SOX2, and CDX2 
expression after H. pylori eradication may be predictive markers 
for metachronous lesions after ER.
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